anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A ketogenic diet (KD) is often used in the treatment of refractory epilepsy. Many studies have found that it also has a positive impact on cognitive comorbidities, but the specific mechanism remains unclear. In many disease models, endoplasmic reticulum stress (ERS) and synaptic plasticity is considered a new therapeutic target for improving cognitive impairment, and it has become a research focus in recent years. Recently, studies have found that a KD has a certain regulatory effect on both ERS and synaptic plasticity, but this result has not been confirmed in epilepsy. To investigate the effect of a KD on ERS and synaptic plasticity. In this study, a rat model of temporal lobe epilepsy (TLE) induced by lithium chloride-pilocarpine was used. After the model was successfully established, the rats in each group were fed a normal diet or a KD for 28 days, and the effect of a KD on the latency and seizure frequency of spontaneous recurrent seizures (SRSs) was observed via video monitoring. Subsequently, a Morris water maze was used to evaluate the spatial learning and memory abilities of the rats in each group; the ultrastructure of the ER and the synapses of the hippocampus were observed by transmission electron microscopy, and the dendritic spine density of the hippocampus was analysed by Golgi staining. Long-term potentiation (LTP) was used to detect the synaptic plasticity of the rats' hippocampi, and the expression of ERS-related proteins and synapse-related proteins was detected by Western blotting. A KD effectively reduced the frequency of SRSs in rats with TLE and improved their learning and memory impairment. Further investigations found that a KD inhibited the up-regulation of glucose-regulated protein 78, phospho-protein kinase-like ER kinase, phosphorylated α subunit of eukaryotic initiation factor 2, activating transcription factor 4 and C/EBP homologous protein expression in the hippocampi of rats with TLE and protected the ultrastructure of the neuronal ER, suggesting that a KD suppressed excessive ERS induced by epilepsy. Concurrently, we also found that a KD not only improved the synaptic ultrastructure and increased the density of dendritic spines in rats with TLE but also reversed the epilepsy-induced LTP deficit to some extent. More importantly, the expression of postsynaptic density protein 95, synaptotagmin-1 and synaptosomal-associated protein 25 in the hippocampi of rats with epilepsy was significantly increased after KD intervention. The study findings indicate that a KD improves learning and memory impairment in rats with epilepsy, possibly by regulating ERS and synaptic plasticity.
PURPOSE:To obtain the title product with the enzyme stabilized, capable of promoting protein-degradative activity by incorporating a powdery or granular enzyme-formulated toiletry product composition with a peptide such as collagen, albumin or elastin. CONSTITUTION:The objective product can be obtained by incorporating (A) powdery or granular enzyme-containing toiletry product composition with (B) pref. 001-20.0 (esp. 0.05-10.0)wt.% of a peptide such as collagen, albumin or elastin. The present product is stabilized in the enzyme contained and capable of promoting protein degradative activity, also having favorable use feeling with the effects unique to the enzyme induced. Incorporation of the peptide plays a role of promoting the performance of the present toiletry product. The present products include bath agents, cleansing bases, powdery detergents for clothes, body powder, tooth powder, etc.
The invention discloses a grease stabilizer, a preparation method and application thereof, and belongs to the technical field of cosmetics. The oil stabilizer comprises a composition for improving the stability of oil; the composition comprises at least two of mastic extract, rosemary leaf extract, pentaerythritol tetrakis (di-tert-butyl hydroxyhydrocinnamate), tocopherol acetate, tocopherol succinate, tocopherol palmitate, ethylhexyl methoxycinnamate and hydroxydecyl ubiquinone. The oil stabilizer can achieve a good oil stabilizing effect by adding a small amount of the oil stabilizer, can inhibit the oxidation of lipid in high oil, can enrich the nutritional function of the oil, and has the advantages of safety and no toxicity. The preparation method is simple and easy to operate. The composite material can obtain better effect by improving the stability of the grease. The cosmetic containing the oil stabilizer has good stability in the aspects of heat resistance, cold resistance, alternation, illumination and the like.
Healthy subjects will be asked to participate in the healthy control testing session. This group will participate in 1 two hour testing session.
Hormone preparations, to be administered by injection or by the mouth, are prepared by causing hormones, or salt-like compounds thereof, or substances containing these, to react with desoxycholic acid, cholic acid, or other bile acid or salt or ester thereof, preferably in presence of an aqueous or other solvent.  Substances promoting solution, other medicinal substances, stabilizing agents, and flavourings may also be added. Hormones specified are adrenalin, thyroxin, insulin, sexual hormones, and endocrine gland preparations; solvents are water, salt solutions, alcohol, acetic ether, acetone, glacial acetic acid or mixtures thereof; solution-promoting substances are lipoids, fats, oils, oleic acid and stearic acid or mixtures thereof; medicinal ingredients are lipoids, phosphatides and vitamines; stabilizing ingredients are benzoic acid, alcohol and chloroform; flavourings are sugar, vanillin and almond oil.  In carrying out the reaction the bile acid may be dissolved in a solvent and the hormone added, or a solution of a hormone together with a solution of a bile acid may be introduced into oleic acid or ground nut oil, or the ingredients may be brought into reaction in the colloidal state, for instance by means of a colloid mill. A number of specific examples are given.  The Specification as open to inspection under Sect. 91 (3) (a) refers also to the treatment of the hormones of the anterior and posterior lobes of the hypophysis, to the use of compounds and derivatives of bile acids and of the solution-promoting substances, and to the use of one of the reactionary substances in heat-liquefied condition.  This subject-matter does not appear in the Specification as accepted.
A computer implemented method for use of encrypted identity on a QR code encoded onto a permanent medium. The system includes mechanism to generate the encrypted identity into a QR code. Also, at patient authentication, the encrypted identity in QR code is read through a custom application. The custom application decrypts the double encrypted global ID using the application encryption key. The server decrypts the application decrypted ID using the server key and date of the encryption. The decrypted global ID is then used to match with the patient information.
The present invention provides an application of composite interferon shown on SEQ. ID. NO: 1 to prepare medicament for treating SARS diseases. The present invention also provides a medical composition for treating SARS diseases, which comprises the composite interferon shown on SEQ. ID. NO: 1 with effective dose for treatment and a medical carrier.
There are many different types of cementless anatomically adapted Total Hip Arthroplasties (THAs) on the market, the Anatomic Benoist Gerard (ABG) I and II are such types of cementless THAs. In this retrospective single-centre study we evaluated the overall survival with revision for any reason and aseptic loosening as endpoint at more than 11 years follow-up. Between 2000 and 2004, 244 cementless THAs were performed in 230 patients in a primary care hospital. At a mean of 11.3 years follow-up (range 9.8 - 12.8 years) clinical examination, plain radiography and Patient Reported Outcome Measures (PROMs) were obtained and analysed. The PROMs consisted of the Oxford Hip Score (OHS) and the Western Ontario and McMaster University Index (WOMAC). At a mean of 11.3 years follow-up 32 patients (13.1%) had died of unrelated causes. Of the remaining cohort all 198 patients (212 THAs) have been reached for evaluation. There were no patients considered as lost to follow-up. At a mean of 11.3 years 11 patients (11 THAs) have had a revision of either the femoral implant or acetabular component resulting in an overall survival of 95.5%. There was no statistically significant difference (p=0.564) in survival between the ABG I and II THAs. Radiographic there were no changes between the ABG I and II last follow up. The ABG II performed statistically significant better in PROMs. We concluded that both anatomically adapted hydroxyapatite coated cementless THAs show excellent survival at more than 11 years follow-up.
PURPOSE: Surgery close to or in contact with the ventricular system is challenging due to the complications. We sought to evaluate the effectiveness and safety of TachoSil® as a ventricular sealant in preventing complications after cranial surgery with an open ventricular system (OVS).
METHODS: This is a single-center and prospective cohort study We included patients who underwent elective surgery for supratentorial craniotomy and periventricular pathology between December 2020 and November 2023. We registered surgical complications arising from CSF dynamics (such as percutaneous cerebrospinal fluid (CSF) leakage, hydrocephalus, pseudomeningocele), infections, and other complications (postsurgical hematoma) adverse drug reactions (ADRs), reintervention or hospital readmission up to 90 days after surgery.
RESULTS: Forty interventions were performed on 39 patients, whose median age was 56 years. Eleven patients (28.2%) had antecedents of previous surgery in the same location, 5 (12.8%) had previously received radiotherapy and chemotherapy, and 11 (28.2%) were smokers. Twenty-four patients (60%) underwent surgery for high-grade glioma, 8 (20%) for low-grade gliomas, 6 (15%) for metastasis and 2 (5%) for meningioma. Throughout the study and up to 90 days after surgery, none of the patients presented an ADR. Only 2 patients (5%) presented with a surgery complications derived from ventricular opening (one patient with a percutaneous CSF leakage and one patients with external hydrocephalus). Both patients resolved with a ventriculoperitoneal shunt.
CONCLUSIONS: TachoSil® is a dural sealant that can be used safely and effectively intraparenchymally in patients whose surgery involves a ventricular opening. Only 5% of treated patients presented complications arising from CSF hydrodynamics. No patients had pseudomeningocele, infections or complications related to the use of this sealant. To confirm these positive results, randomized and comparative clinical trials assessing the efficacy of TachoSil® in patients after cranial surgery with an OVS are essential.
TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: This study was registered in the Clinical Trials.gov (NCT05717335). Date May 1st, 2022.
This is a prospective cross-sectional interventional design. 100 COPD patients who applied to Mersin University Faculty of Medicine Hospital Chest Diseases Clinic between 01.10.2019-01.04.2020 will be taken. 35 healthy participants with smoking history and 35 healthy participants without smoking history who were admitted to our clinic within the same date range will be taken as control group. Impulse oscillometric pulmonary function tests will be performed to all participants. Thorax computed tomography will be performed to evaluate small airway dysfunction. To evaluate the degree of disease inflammation and phenotype in COPD patients, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. The blood eosinophil level will be studied to determine the COPD phenotype. To assess symptom control in patients with COPD, mMRC(Modified Medical Research Council) dyspnea scale will be administered. The COPD assessment test (CAT) will be applied to measure the quality of life. All patients will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for COPD. The effect of small airway dysfunction on the disease severity and control degree, disease phenotypes and quality of life, and the effect on the risk of exacerbation will be analyzed.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use having preventing effects or improving effects on aging of skin such as occurrence of wrinkles or hair growth suppressing effects, etc., by including a specific malonamide derivative (salt) as an active ingredient. SOLUTION: This skin preparation for external use is obtained by including a malonamide derivative (salt) represented by formula I [R1 is H, an alkyl, an alkenyl or the like; R2 is H, a (substituted)alkyl, a (substituted)alkenyl or the like; R3 is H, an alkyl or the like; R4 is H, a (substituted)alkyl or the like or R3 and R4 together may form a heterocyclic ring with the adjacent N: R5 is OH, an alkoxy, an amino acid residue or the like; n is 0-5] (e.g. a compound represented by formula II) as an active ingredient. The compound represented by formula I can be produced by a method, etc., for reacting, e.g. a half ester of malonic acid represented by formula III with an amino acid ester represented by formula IV in the presence of a dehydration condensing agent and then, as necessary, reacting the resultant compound with a base.  The amount of the formulated compound represented by formula I in the skin preparation for external use is preferably about 0.0001-40 wt.%.
PROBLEM TO BE SOLVED: To obtain an ameliorating agent for osteoporosis by including a complex of chitin and calcium therein. SOLUTION: This agent comprises a complex of chitin-calcium complex of a chitin and an inorganic substance such as calcium. The chitin-calcium complex is derived from an outer skeleton of crustaceans, e.g. a lobster or a shrimp or a crab and is obtained by carrying out the deproteinizing treatment of the substance derived therefrom with a dilute alkali without performing a deashing treatment while leaving the ash such as the calcium so as not to deteriorate the fibrous structure of the chitin at least twice, then washing the treatment product with water and drying the washed product. The chitin-calcium complex preferably contains 15-30% chitin and 20-35% calcium therein.  The calcium contained therein can be made to migrate to each bone site of a living body in the coexistence of the chitin and the agent is useful not only as a simple ameliorating agent but also even as a therapeutic agent in treating osteoporosis.
The invention provides a protein for detecting foot-and-mouth disease virus antibodies and application thereof, belonging to the field of biotechnology detection. The sequence of the protein is shown as SEQ ID No. 3, and the sequence of the gene is shown as SEQ ID No. 2. The invention also provides a recombinant vector or cell containing the gene, and a foot-and-mouth disease virus antibody competition ELISA detection kit. The kit comprises an ELISA plate coated by the protein and a detection antibody, wherein the detection antibody is secreted by a hybridoma cell strain FMDV-3B-1 with the preservation number of CGMCC No. 45034. The foot-and-mouth disease antibody competition ELISA kit established by the invention realizes high-sensitivity and high-specificity detection on the foot-and-mouth disease antibody.
FIELD: biotechnology. SUBSTANCE: strain of cultured cells of plant cardiophyllous madder (Rubia cordifolia L.) is obtained in the Biology-Soil institute DVO RAN and deposited in All-Russian collection of cellular cultures of the higher plants at Institute of Plant Physiology RAN at the index RC-1. The strain RC-1 is obtained from wild growing plant cardiophyllous madder collected in Anuchinsky district of Primorski Territory. The strain is the callus tissue of friable consistence, yellow-orange color. The strain is cultured at the accumulating regime on agarized nutrient medium. The strain is the highly productive source of value anthraquinone pigments - munjistin and purpurin. An average content of pigments is 0.89% of dry cells mass. Anthraquinones are the effective agent for treatment of patients with renal calculosis disease and liver diseases since they are biologically active substances. EFFECT: strain indicated above, high yield of value pigments, value curative properties. 2 tbl, 1 ex
The aim of this study was to investigate the genotoxic effect of Propineb fungicide at different concentrations (0.167, 0.335 and 0.670 mg L-1) and different treatment times (24, 48, 72 and 96 h) on Danio rerio. At the end of the treatment periods, blood was collected from the fish with a heparin injector; smear preparations were prepared, fixed and stained. In the prepared preparations, the numbers of cells with MN and erythrocyte nucleus abnormalities were examined. It was found that propineb increased micronucleus formation at all treatment times and concentrations and induced the formation of erythrocytes with morphological abnormal nuclei such as segmented, kidney-shaped, notched, vacuolated nuclei and binucleated. The increase in micronucleus formation and the number of erythrocytes with abnormal nuclei were found to be concentration and treatment time-dependent. In conclusion, in this study, Danio rerio erythrocytes were used to evaluate the genotoxic effects of propineb fungicide on aquatic organisms, which have an important place in environmental risk assessment criteria. Since fungicides used in agricultural control such as propineb may have the potential to be genotoxic to aquatic organisms, the results of toxicity tests should be taken into consideration in the selection and use of concentrations of these chemicals.
The safety and effectiveness of azelastine hydrochloride and fluticasone propionate nasal spray for seasonal allergic rhinitis have been established in pediatric patients aged 6 years and older. Use of azelastine hydrochloride and fluticasone propionate nasal spray for this indication in pediatric patients 6 to 11 years of age is supported by evidence from controlled clinical trials (416 patients 6 to 11 years of age with allergic rhinitis were treated with azelastine hydrochloride and fluticasone propionate nasal spray) [see Adverse Reactions (6.1) and Clinical Studies (14)].

Sixty-one patients ages 4-5 years of age were treated with azelastine hydrochloride and fluticasone propionate nasal spray in the pediatric studies described above. Safety findings in children 4-5 years of age were similar to those in children 6-11 years of age, but effectiveness has not been established. 

Safety and effectiveness of azelastine hydrochloride and fluticasone propionate nasal spray have not been established in pediatric patients below the age of 4 years.

Controlled clinical studies have shown that nasal corticosteroids may cause a reduction in growth velocity in pediatric patients. This effect has been observed in the absence of laboratory evidence of HPA axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The long-term effects of this reduction in growth velocity associated with nasal corticosteroids, including the impact on final adult height, are unknown. The potential for “catch-up” growth following discontinuation of treatment with nasal corticosteroids has not been adequately studied. The growth of pediatric patients receiving nasal corticosteroids, including azelastine hydrochloride and fluticasone propionate nasal spray, should be monitored routinely (e.g., via stadiometry). The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained and the risks/benefits of treatment alternatives.
Pain is the most common symptom for which patients seek medical attention. Existing treatments for pain control are largely ineffective due to the lack of an accurate way to objectively measure pain intensity and a poor understanding of the etiology of pain. Thrombospondin 4(TSP4), a member of the thrombospondin gene family, is expressed in neurons and astrocytes and induces pain by interacting with the calcium channel alpha-2-delta-1 subunit (Cavα2δ1). In the present study we show that TSP4 expression level correlates positively with pain intensity, suggesting that TSP4 could be a novel candidate of pain indicator. Using RNAi-lentivirus (RNAi-LV) to knock down TSP4 both in vivo and in vitro, together with electrophysiological experiments involving paired patch-clamp recordings of evoked action potentials and post-synaptic currents in cultured neurons, we found that TSP4 contributes to the development of bone cancer pain, neuropathic pain, and inflammatory pain. This effect is mediated by regulation of neuron excitability via inhibition of synapsin I (Syn I) and modulation of excitatory and inhibitory presynaptic transmission via regulation of vesicular glutamate transporter 2(Vglut2), vesicular GABA transporter (VGAT), and glutamate decarboxylase (GAD) expression. The present study provides a replicable, predictive, valid indicator of pain and demonstrated the underlying molecular and electrophysiological mechanisms by which TSP4 contributes to pain.
This group will consist of participants \>14 years old with various types of corneal irregularities. Their data will be compared against participants with healthy corneas. Data for this group will be gathered only once.
Poor sleep in children is a growing public health concern worldwide. Sleep health is a multidimensional construct (sleep-related behaviors, satisfaction, alertness, timing, efficiency, and duration) influenced by a complex interplay of social-ecological factors. Sleep impacts a range of physical health and neurodevelopmental outcomes including children's executive function (EF), growth, and obesity risk, which are public health priorities in low-and-middle-income countries (LMICs). Early EFs are predictive of social competence and academic performance and economic achievement in later life. Childhood obesity is a rapidly growing health issue in LMICs and a leading risk factor of diabetes. Interventions targeting modifiable sleep behavior have the potential to improve long-term physical and neurodevelopmental outcomes for millions of children in LMICs. Most data on children's sleep health are from high-income settings, and the recommendations based on these studies are not directly relevant to LMICs. Emerging evidence shows multiple cross-cultural differences in sleep dimensions in early childhood. Children in Asian countries have a significantly later bedtime and shorter sleep duration compared to children in Western countries. Recent research and our preliminary data suggest that 40% of preschool children in urban Bangladesh sleep less than the recommended duration (10-13 hours) by the World Health Organization (WHO). Evidence from high-income settings links individual (e.g., age, screen time, physical activity), interpersonal (e.g., maternal mood, parenting stress, mother-child interaction), and social (e.g., social socioeconomic condition, household crowding) factors to childhood sleep. We aim to study the determinants of sleep health using a socioecological framework, and the role of sleep health on growth and neurodevelopmental outcomes among 300 preschool children in Bangladesh, a lower-middle-income country in South Asia.